Guggenheim analyst Yatin Suneja reiterated a Buy rating and {REMOVEPT} price target on Zenas Biopharma (NASDAQ: ZBIO).The analyst commented: "ZBIO's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE